ARTICLE | Clinical News
SU101 inhibitor of cell division signals sent by platelet-derived growth factor: Began Phase I trial of safety and pharmacokinetics of multiple doses
October 2, 1995 7:00 AM UTC
Sugen Inc. (SUGN), Redwood City, Calif. Product: SU101 inhibitor of cell division signals sent by platelet-derived growth factor, at its receptor, a tyrosine kinase on cell surfaces Indication: Solid ...